Journal article

Neuroplastin beta mediates S100A8/A9-induced lung cancer disseminative progression

I WAYAN SUMARDIKA Youyi Chen Nahoko Tomonobu Rie Kinoshita I MADE WINARSA RUMA Hiroki Sato Eisaku Kondo Yusuke Inoue Hitoshi Murata Ken ichi Yamamoto Endy Widya Putranto Toshihiko Hibino Masahiro Nishibori Shinichi Toyooka Masakiyo Sakaguchi

Volume : 58 Nomor : 6 Published : 2019, June

Molecular Carcinogenesis

Abstrak

Compiling evidence indicates an unusual role of extracellular S100A8/A9 in cancer metastasis. S100A8/A9 secreted from either cancer cells or normal cells including epithelial and inflammatory cells stimulates cancer cells through S100A8/A9 sensor receptors in an autocrine or paracrine manner, leading to cancer cell metastatic progression. We previously reported a novel S100A8/A9 receptor, neuroplastin-? (NPTN?), which plays a critical role in atopic dermatitis when it is highly activated in keratinocytes by an excess amount of extracellular S100A8/A9 in the inflammatory skin lesion. Interestingly, our expression profiling of NPTN? showed significantly high expression levels in lung cancer cell lines in a consistent manner. We hence aimed to determine the significance of NPTN? as an S100A8/A9 receptor in lung cancer. Our results showed that NPTN? has strong ability to induce cancer-related cellular events, including anchorage-independent growth, motility and invasiveness, in lung cancer cells in response to extracellular S100A8/A9, eventually leading to the expression of a cancer disseminative phenotype in lung tissue in vivo. Mechanistic investigation revealed that binding of S100A8/A9 to NPTN? mediates activation of NFIA and NFIB and following SPDEF transcription factors through orchestrated upstream signals from TRAF2 and RAS, which is linked to anchorage-independent growth, motility and invasiveness. Overall, our results indicate the importance of the S100A8/A9-NPTN? axis in lung cancer disseminative progression and reveal a pivotal role of its newly identified downstream signaling, TRAF2/RAS-NFIA/NFIB-SPDEF, in linking to the aggressive development of lung cancers.